Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14765MR)

This product GTTS-WQ14765MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF8 gene. The antibody can be applied in Anaplastic large cell lymphoma (ALCL), Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001243.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 943
UniProt ID P28908
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ14765MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2482MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ4411MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ1682MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ1027MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ86MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 1121B
GTTS-WQ5300MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ12810MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OMS721
GTTS-WQ13508MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRX002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW